博雅生物(300294) - 2025 Q1 - 季度财报

Financial Performance - The company's operating revenue for Q1 2025 was CNY 535,876,732.90, representing a 19.49% increase compared to CNY 448,452,537.26 in the same period last year[2] - The net profit attributable to shareholders decreased by 8.25% to CNY 139,484,155.03 from CNY 152,024,886.81 year-on-year[3] - The net profit attributable to shareholders after deducting non-recurring gains and losses fell by 19.67% to CNY 102,261,123.10, down from CNY 127,306,750.41 in the previous year[3] - Operating profit for the current period was ¥162,436,766.94, a decrease of 7% from ¥174,748,795.31 in the previous period[19] - Net profit for the current period was ¥139,291,778.48, down 8.1% from ¥151,760,842.43 in the previous period[19] - The net profit attributable to the parent company was approximately ¥139.48 million, a decrease from ¥152.02 million in the previous period, representing a decline of about 8.5%[20] - The total comprehensive income attributable to the parent company was approximately ¥139.11 million, down from ¥152.02 million, reflecting a decrease of around 8.5%[20] - Basic and diluted earnings per share were both ¥0.28, compared to ¥0.30 in the previous period, indicating a decline of approximately 6.67%[20] Cash Flow - The net cash flow from operating activities was negative CNY 42,119,496.62, a decline of 134.00% compared to a positive CNY 123,871,710.13 in the same period last year[4] - Cash inflows from operating activities totaled approximately ¥427.20 million, slightly down from ¥433.67 million, a decrease of about 1.1%[21] - Cash outflows from operating activities increased significantly to approximately ¥469.32 million from ¥309.79 million, resulting in a net cash flow from operating activities of approximately -¥42.12 million[22] - Cash inflows from investment activities were approximately ¥1.45 billion, up from ¥922.01 million, marking an increase of about 57.3%[22] - Cash outflows from investment activities rose to approximately ¥2.12 billion from ¥1.15 billion, leading to a net cash flow from investment activities of approximately -¥669.31 million[22] - The ending cash and cash equivalents balance was approximately ¥585.46 million, down from ¥1.84 billion, indicating a decrease of about 68.3%[22] - The company reported a significant increase in payments to employees, totaling approximately ¥121.99 million, compared to ¥94.45 million in the previous period, an increase of about 29.4%[22] - The company’s cash flow from financing activities resulted in a net outflow of approximately -¥1.70 million, compared to -¥52,856.64 in the previous period, indicating a larger outflow[22] Assets and Liabilities - Total assets at the end of the reporting period increased by 0.92% to CNY 8,478,706,583.73 from CNY 8,401,144,768.99 at the end of the previous year[2] - Total liabilities decreased to ¥852,022,450.92 from ¥913,381,994.27, a reduction of 6.7%[17] - Cash and cash equivalents decreased to ¥586,740,774.48 from ¥1,299,851,770.61, a decline of 54.8%[16] - Inventory slightly decreased to ¥983,308,049.53 from ¥995,427,153.22, a reduction of 1.4%[16] - Non-current assets increased to ¥3,431,232,325.36 from ¥3,342,794,636.95, an increase of 2.6%[17] - The total equity attributable to the parent company increased to ¥7,626,264,685.05 from ¥7,487,150,950.41, reflecting a growth of 1.9%[18] Shareholder Information - The total number of common shareholders at the end of the reporting period is 27,155[10] - The largest shareholder, China Resources Pharmaceutical Group, holds 30.45% of shares, totaling 153,540,253 shares[10] - Shenzhen Gaotejia Investment Group holds 11.31% of shares, totaling 57,049,640 shares, with 16,450,000 shares pledged[10] - The top ten shareholders collectively hold significant stakes, with the top three accounting for over 45% of total shares[10] - The company has a total of 0 preferred shareholders at the end of the reporting period[10] - The company has not reported any changes in the number of restricted shares during the reporting period[12] Research and Development - Research and development expenses decreased by 44.40% to CNY 10,566,848.19, primarily due to reduced investment in the Pibin project compared to the previous year[9] - Research and development expenses for the current period were ¥10,566,848.19, down 44.5% from ¥19,006,039.85 in the previous period[19] Regulatory Approvals - The company received approval to set up a blood plasma collection station in Daqing, Inner Mongolia, as of January 2025[12] - The company obtained a clinical trial approval for subcutaneous immunoglobulin for primary immunodeficiency disease in April 2025[13] Shareholder Actions - The controlling shareholder plans to increase its stake by at least 1% (5,042,400 shares) within six months starting from November 8, 2024[14] - As of April 8, 2025, the controlling shareholder has cumulatively increased its stake by 1.17% (5,899,700 shares) since November 8, 2024[14] Impact of Acquisitions - The company's gross profit margin was impacted by the acquisition of Green Cross, with operating costs rising by 71.38% to CNY 247,566,329.70[8] - The company reported a significant increase in accounts receivable by 31.94% to CNY 591,733,607.73, attributed to revenue growth and a decline in cash collections[8]